171
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA

      research-article
      The Cancer Genome Atlas Research Network
      Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Genetic changes underlying clear cell renal cell carcinoma (ccRCC) include alterations in genes controlling cellular oxygen sensing (e.g. VHL) and the maintenance of chromatin states (e.g. PBRM1). We surveyed more than 400 tumors using different genomic platforms and identified 19 significantly mutated genes. The PI3K/Akt pathway was recurrently mutated, suggesting this pathway as a potential therapeutic target. Widespread DNA hypomethylation was associated with mutation of the H3K36 methyltransferase SETD2, and integrative analysis suggested that mutations involving the SWI/SNF chromatin remodeling complex ( PBRM1, ARID1A, SMARCA4) could have far-reaching effects on other pathways. Aggressive cancers demonstrated evidence of a metabolic shift, involving down-regulation of genes involved in the TCA cycle, decreased AMPK and PTEN protein levels, up-regulation of the pentose phosphate pathway and the glutamine transporter genes, increased acetyl-CoA carboxylase protein, and altered promoter methylation of miR-21 and GRB10. Remodeling cellular metabolism thus constitutes a recurrent pattern in ccRCC that correlates with tumor stage and severity and offers new views on the opportunities for disease treatment.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Prediction of mammalian microRNA targets.

          MicroRNAs (miRNAs) can play important gene regulatory roles in nematodes, insects, and plants by basepairing to mRNAs to specify posttranscriptional repression of these messages. However, the mRNAs regulated by vertebrate miRNAs are all unknown. Here we predict more than 400 regulatory target genes for the conserved vertebrate miRNAs by identifying mRNAs with conserved pairing to the 5' region of the miRNA and evaluating the number and quality of these complementary sites. Rigorous tests using shuffled miRNA controls supported a majority of these predictions, with the fraction of false positives estimated at 31% for targets identified in human, mouse, and rat and 22% for targets identified in pufferfish as well as mammals. Eleven predicted targets (out of 15 tested) were supported experimentally using a HeLa cell reporter system. The predicted regulatory targets of mammalian miRNAs were enriched for genes involved in transcriptional regulation but also encompassed an unexpectedly broad range of other functions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Understanding the language of Lys36 methylation at histone H3.

            Histone side chains are post-translationally modified at multiple sites, including at Lys36 on histone H3 (H3K36). Several enzymes from yeast and humans, including the methyltransferases SET domain-containing 2 (Set2) and nuclear receptor SET domain-containing 1 (NSD1), respectively, alter the methylation status of H3K36, and significant progress has been made in understanding how they affect chromatin structure and function. Although H3K36 methylation is most commonly associated with the transcription of active euchromatin, it has also been implicated in diverse processes, including alternative splicing, dosage compensation and transcriptional repression, as well as DNA repair and recombination. Disrupted placement of methylated H3K36 within the chromatin landscape can lead to a range of human diseases, underscoring the importance of this modification.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.

              The evolutionarily conserved serine-threonine kinase mammalian target of rapamycin (mTOR) plays a critical role in regulating many pathophysiological processes. Functional characterization of the mTOR signaling pathways, however, has been hampered by the paucity of known substrates. We used large-scale quantitative phosphoproteomics experiments to define the signaling networks downstream of mTORC1 and mTORC2. Characterization of one mTORC1 substrate, the growth factor receptor-bound protein 10 (Grb10), showed that mTORC1-mediated phosphorylation stabilized Grb10, leading to feedback inhibition of the phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated, mitogen-activated protein kinase (ERK-MAPK) pathways. Grb10 expression is frequently down-regulated in various cancers, and loss of Grb10 and loss of the well-established tumor suppressor phosphatase PTEN appear to be mutually exclusive events, suggesting that Grb10 might be a tumor suppressor regulated by mTORC1.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                3 August 2013
                23 June 2013
                4 July 2013
                04 January 2014
                : 499
                : 7456
                : 43-49
                Article
                NIHMS472502
                10.1038/nature12222
                3771322
                23792563
                ba69c648-850f-4cae-881e-59247c38692b

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Human Genome Research Institute : NHGRI
                Award ID: U54 HG003273 || HG
                Funded by: National Human Genome Research Institute : NHGRI
                Award ID: U54 HG003079 || HG
                Funded by: National Human Genome Research Institute : NHGRI
                Award ID: U54 HG003067 || HG
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA144025 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143883 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143882 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143867 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143866 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143858 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143848 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143845 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143843 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143840 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143835 || CA
                Funded by: National Cancer Institute : NCI
                Award ID: U24 CA143799 || CA
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article